Literature DB >> 28365413

Ultra-performance liquid chromatography tandem mass spectrometry for determination of Direct Acting Antiviral drugs in human liver fine needle aspirates.

Andrew J Ocque1, Colleen E Hagler2, Robin DiFrancesco2, Gene D Morse2, Andrew H Talal3.   

Abstract

An ultra-performance liquid chromatography with triple quadrupole mass spectrometry method was developed and validated for the determination of direct acting antiviral drug concentrations in human liver fine needle aspirates. Liver fine needle aspirate (FNA) biopsy samples were homogenized in acetonitrile to stabilize the analytes and precipitate protein. The acetonitrile supernatants were diluted with internal standards and mobile phase. Separation was achieved with a Waters Acquity BEH C18 column (50×2.1mm, 1.7um) with a gradient elution of 0.1% formic acid in water and acetonitrile. The total run time was 4.25min. Detection of analytes was achieved using electrospray ionization (positive mode) and triple quadrupole selected reaction monitoring. Standard curve concentrations ranged from 12.5 to 5000ng/mL for dasabuvir and the m1 metabolite of dasabuvir, 1.25 to 2500ng/mL for ombitasvir and ritonavir, and 5.00 to 5000ng/mL for paritaprevir. The intra- and inter-day accuracy and precision were less than 13.7% in low, medium, and high quality control samples. The validated method was applied to the analysis of a liver fine needle aspirate of a patient undergoing direct acting antiviral therapy for hepatitis C virus.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dasabuvir; Fine needle aspirate; Liver; Ombitasvir; Paritaprevir; UPLC–MS/MS

Mesh:

Substances:

Year:  2017        PMID: 28365413      PMCID: PMC5472061          DOI: 10.1016/j.jchromb.2017.03.020

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  13 in total

Review 1.  Fine needle aspiration in the diagnosis of liver neoplasms: a review.

Authors:  H Y Houn; M M Sanders; E M Walker; A A Pappas
Journal:  Ann Clin Lab Sci       Date:  1991 Jan-Feb       Impact factor: 1.256

2.  Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.

Authors:  Jacob Lalezari; J Greg Sullivan; Peter Varunok; Edward Galen; Kris V Kowdley; Vinod Rustgi; Humberto Aguilar; Franco Felizarta; Barbara McGovern; Martin King; Akshanth R Polepally; Daniel E Cohen
Journal:  J Hepatol       Date:  2015-04-01       Impact factor: 25.083

3.  Development and validation of a UPLC-MS/MS method for the simultaneous determination of paritaprevir and ritonavir in rat liver.

Authors:  Andrew J Ocque; Colleen E Hagler; Robin Difrancesco; Yvonne Woolwine-Cunningham; Cindy J Bednasz; Gene D Morse; Andrew H Talal
Journal:  Bioanalysis       Date:  2016-06-09       Impact factor: 2.681

4.  Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers.

Authors:  R M Menon; C E Klein; T J Podsadecki; Y-L Chiu; S Dutta; W M Awni
Journal:  Br J Clin Pharmacol       Date:  2016-02-24       Impact factor: 4.335

5.  Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

Authors:  G L Davis; L A Balart; E R Schiff; K Lindsay; H C Bodenheimer; R P Perrillo; W Carey; I M Jacobson; J Payne; J L Dienstag
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

6.  A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma.

Authors:  Alessandra Ariaudo; Fabio Favata; Amedeo De Nicolò; Marco Simiele; Luca Paglietti; Lucio Boglione; Chiara Simona Cardellino; Chiara Carcieri; Giovanni Di Perri; Antonio D'Avolio
Journal:  J Pharm Biomed Anal       Date:  2016-04-20       Impact factor: 3.935

Review 7.  Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice.

Authors:  J E Arends; P A M Kracht; A I M Hoepelman
Journal:  Clin Microbiol Infect       Date:  2016-06-10       Impact factor: 8.067

8.  Gene expression analysis in serial liver fine needle aspirates.

Authors:  S Lejnine; M J Marton; I-M Wang; B J Howell; A L Webber; J W Maxwell; N Shire; V Malkov; J Lunceford; M Zeremski; A Sun; M Ruddy; A H Talal
Journal:  J Viral Hepat       Date:  2014-01-29       Impact factor: 3.728

9.  Metabolism and Disposition of Hepatitis C Polymerase Inhibitor Dasabuvir in Humans.

Authors:  Jianwei Shen; Michael Serby; Aimee Reed; Anthony J Lee; Rajeev Menon; Xiaomei Zhang; Kennan Marsh; Xia Wan; Olga Kavetskaia; Volker Fischer
Journal:  Drug Metab Dispos       Date:  2016-05-13       Impact factor: 3.922

Review 10.  Direct anti-HCV agents.

Authors:  Xingquan Zhang
Journal:  Acta Pharm Sin B       Date:  2015-11-24       Impact factor: 11.413

View more
  3 in total

1.  Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage.

Authors:  Andrew H Talal; Emily O Dumas; Barbara Bauer; Richard M Rejman; Andrew Ocque; Gene D Morse; Danijela Lucic; Gavin A Cloherty; Jennifer King; Jiuhong Zha; Hongtao Zhang; Daniel E Cohen; Nancy Shulman; Jean-Michel Pawlotsky; Christophe Hézode
Journal:  J Infect Dis       Date:  2018-01-17       Impact factor: 5.226

2.  Development and Validation of a New LC-MS/MS Analytical Method for Direct-Acting Antivirals and Its Application in End-Stage Renal Disease Patients.

Authors:  Faten Farouk; Dina Wahba; Sherif Mogawer; Shaimaa Elkholy; Ahmed Elmeligui; Reham Abdelghani; Salwa Ibahim
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2020-02       Impact factor: 2.441

Review 3.  Detection and quantification of Covid-19 antiviral drugs in biological fluids and tissues.

Authors:  Maria A Acquavia; Luca Foti; Raffaella Pascale; Antonia Nicolò; Vincenzo Brancaleone; Tommaso R I Cataldi; Giuseppe Martelli; Laura Scrano; Giuliana Bianco
Journal:  Talanta       Date:  2020-11-05       Impact factor: 6.057

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.